Innovative Product Launches DORC has demonstrated a strong track record of developing and launching advanced ophthalmic surgical tools, such as the EVA NEXUS platform and TissueBlue stains, which are widely adopted and FDA-approved. This indicates a proactive approach to product innovation, creating opportunities to offer complementary or upgraded solutions tailored to surgeons' needs.

Strategic Industry Integration The recent integration with ZEISS enhances DORC’s market positioning and presents a strategic opportunity to collaborate or expand sales through ZEISS’s extensive global network, particularly as its innovative platforms like EVA NEXUS are now embedded within ZEISS’s broader surgical offerings.

Global Regulatory Approvals DORC’s success in obtaining critical regulatory approvals such as FDA and Health Canada for key products like TissueBlue signifies strong compliance and market readiness, simplifying the process of entering or expanding sales in regulated markets such as North America with a ready supply of validated, trusted devices.

Growing Market Penetration With over 100,000 surgeries utilizing TissueBlue and significant surgeon preference in the US market, DORC has established a solid user base that can be leveraged for cross-selling new products or upgrades, and for expanding into other ophthalmic surgical segments.

Robust Financial Backing Backed by substantial funding of $94 million and recent acquisition by Eurazeo for nearly $300 million, DORC benefits from strong financial support, providing opportunities for targeted partnership proposals, co-marketing initiatives, and joint ventures to accelerate penetration into emerging markets.